



## Clinical trial results:

### A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglobulin, Privigen®) in Adults with Systemic Sclerosis (SSc)

#### Summary

EudraCT number	2018-003149-41
Trial protocol	DE FR GB IT
Global end of trial date	17 May 2022

#### Results information

Result version number	v1 (current)
This version publication date	23 June 2023
First version publication date	23 June 2023

#### Trial information

##### Trial identification

Sponsor protocol code	IgPro20_2001
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04137224
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	CSL Behring
Sponsor organisation address	Emil-von-Behring-Strasse 76, Marburg, Germany, 35041
Public contact	Trial Registration Coordinator, CSL Behring LLC, +1 610-878-4000, clinicaltrials@cslbehring.com
Scientific contact	Trial Registration Coordinator, CSL Behring LLC, +1 610-878-4000, clinicaltrials@cslbehring.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 May 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	17 May 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study was to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc). The pharmacokinetic study aim was to evaluate the relative bioavailability of IgPro20, and characterize pharmacokinetics of IgPro20 and IgPro10, respectively, in subjects with dcSSc. Safety, tolerability, and pharmacokinetics of IgPro10 was also evaluated.

Protection of trial subjects:

This study was carried out in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and standard operating procedures for clinical research and development at CSL Behring.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 September 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 17
Country: Number of subjects enrolled	United Kingdom: 6
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Australia: 2
Worldwide total number of subjects	27
EEA total number of subjects	19

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	25
From 65 to 84 years	2
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Subjects were enrolled at study centers in Australia, Germany, Italy, Poland, and the United Kingdom from 19 September 2019 to 17 May 2022.

### Pre-assignment

Screening details:

A total of 30 subjects were screened, of which 27 subjects were enrolled and randomised to Sequence A or Sequence B in this study.

### Period 1

Period 1 title	Treatment Period 1 (Week 1 to Week 16)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Sequence A (IgPro20/IgPro10)

Arm description:

Subjects received IgPro20 of a total dose of 0.5 grams per kilogram (g/kg) over 2 sessions per week as a subcutaneous (SC) injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an intravenous (IV) infusion for up to 16 weeks in Treatment Period 2.

Arm type	Experimental
Investigational medicinal product name	IgPro20
Investigational medicinal product code	
Other name	Hizentra
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

A total dose of 0.5 g/kg was administered over 2 sessions per week for up to 16 weeks.

Investigational medicinal product name	IgPro10
Investigational medicinal product code	
Other name	Privigen
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

A total dose of 2 g/kg was administered over 2-5 sessions on consecutive days every 4 weeks for up to 16 weeks.

<b>Arm title</b>	Sequence B (IgPro10/IgPro20)
------------------	------------------------------

Arm description:

Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.

Arm type	Experimental
Investigational medicinal product name	IgPro10
Investigational medicinal product code	
Other name	Privigen
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

A total dose of 2 g/kg was administered over 2-5 sessions on consecutive days every 4 weeks for up to 16 weeks.

Investigational medicinal product name	IgPro20
Investigational medicinal product code	
Other name	Hizentra
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

A total dose of 0.5 g/kg was administered over 2 sessions per week for up to 16 weeks.

<b>Number of subjects in period 1</b>	Sequence A (IgPro20/IgPro10)	Sequence B (IgPro10/IgPro20)
Started	13	14
Completed	12	13
Not completed	1	1
Adverse event	1	-
Withdrawal by subject	-	1

**Period 2**

Period 2 title	Treatment Period 2 (Week 17 to Week 32)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Sequence A (IgPro20/IgPro10)

**Arm description:**

Subjects received IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 2.

Arm type	Experimental
Investigational medicinal product name	IgPro20
Investigational medicinal product code	
Other name	Hizentra
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

A total dose of 0.5 g/kg was administered over 2 sessions per week for up to 16 weeks.

Investigational medicinal product name	IgPro10
Investigational medicinal product code	
Other name	Privigen
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

---

**Dosage and administration details:**

A total dose of 2 g/kg was administered over 2-5 sessions on consecutive days every 4 weeks for up to 16 weeks.

<b>Arm title</b>	Sequence B (IgPro10/IgPro20)
------------------	------------------------------

**Arm description:**

Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.

Arm type	Experimental
Investigational medicinal product name	IgPro10
Investigational medicinal product code	
Other name	Privigen
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

A total dose of 2 g/kg was administered over 2-5 sessions on consecutive days every 4 weeks for up to 16 weeks.

Investigational medicinal product name	IgPro20
Investigational medicinal product code	
Other name	Hizentra
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

A total dose of 0.5 g/kg was administered over 2 sessions per week for up to 16 weeks.

<b>Number of subjects in period 2<sup>[1]</sup></b>	<b>Sequence A (IgPro20/IgPro10)</b>	<b>Sequence B (IgPro10/IgPro20)</b>
Started	12	13
Completed	13	12
Not completed	0	1
Adverse event	-	1
Joined	1	0
Transferred in from other group/arm	1	-

---

**Notes:**

[1] - The number of subjects transferring in and out of the arms in the period are not the same. It is expected the net number of transfers in and out of the arms in a period, will be zero.

Justification: 13 subjects have started and completed the sequence A in treatment period 2.

## Baseline characteristics

### Reporting groups

Reporting group title	Sequence A (IgPro20/IgPro10)
Reporting group description: Subjects received IgPro20 of a total dose of 0.5 grams per kilogram (g/kg) over 2 sessions per week as a subcutaneous (SC) injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an intravenous (IV) infusion for up to 16 weeks in Treatment Period 2.	
Reporting group title	Sequence B (IgPro10/IgPro20)
Reporting group description: Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.	

Reporting group values	Sequence A (IgPro20/IgPro10)	Sequence B (IgPro10/IgPro20)	Total
Number of subjects	13	14	27
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	51.4 ± 12.22	47.4 ± 12.91	-
Gender categorical Units: Subjects			
Female	10	8	18
Male	3	6	9
Ethnicity Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	12	14	26
Unknown or Not Reported	1	0	1
Race Units: Subjects			
White	13	13	26
Other	0	1	1

### Subject analysis sets

Subject analysis set title	Sequence A: IgPro10
Subject analysis set type	Safety analysis
Subject analysis set description: Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 2.	
Subject analysis set title	Sequence A: IgPro20
Subject analysis set type	Safety analysis
Subject analysis set description: Subjects received IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 1.	

Subject analysis set title	Sequence B: IgPro10
Subject analysis set type	Safety analysis
Subject analysis set description:	
Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1.	
Subject analysis set title	Sequence B: IgPro20
Subject analysis set type	Safety analysis
Subject analysis set description:	
Subjects received IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.	

Reporting group values	Sequence A: IgPro10	Sequence A: IgPro20	Sequence B: IgPro10
Number of subjects	13	13	14
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	0	0	0
standard deviation	± 0	± 0	± 0
Gender categorical Units: Subjects			
Female	0	0	0
Male	0	0	0
Ethnicity Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	0	0	0
Unknown or Not Reported	0	0	0
Race Units: Subjects			
White	0	0	0
Other	0	0	0

Reporting group values	Sequence B: IgPro20		
Number of subjects	13		
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	0		
standard deviation	± 0		
Gender categorical Units: Subjects			
Female	0		
Male	0		
Ethnicity Units: Subjects			
Hispanic or Latino	0		
Not Hispanic or Latino	0		



Unknown or Not Reported	0		
Race			
Units: Subjects			
White	0		
Other	0		

## End points

### End points reporting groups

Reporting group title	Sequence A (IgPro20/IgPro10)
-----------------------	------------------------------

Reporting group description:

Subjects received IgPro20 of a total dose of 0.5 grams per kilogram (g/kg) over 2 sessions per week as a subcutaneous (SC) injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an intravenous (IV) infusion for up to 16 weeks in Treatment Period 2.

Reporting group title	Sequence B (IgPro10/IgPro20)
-----------------------	------------------------------

Reporting group description:

Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.

Reporting group title	Sequence A (IgPro20/IgPro10)
-----------------------	------------------------------

Reporting group description:

Subjects received IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 2.

Reporting group title	Sequence B (IgPro10/IgPro20)
-----------------------	------------------------------

Reporting group description:

Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.

Subject analysis set title	Sequence A: IgPro10
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 2.

Subject analysis set title	Sequence A: IgPro20
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Subjects received IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 1.

Subject analysis set title	Sequence B: IgPro10
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1.

Subject analysis set title	Sequence B: IgPro20
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Subjects received IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.

### Primary: Number of Subjects With at Least one Adverse Event (AE) for IgPro20

End point title	Number of Subjects With at Least one Adverse Event (AE) for IgPro20 <sup>[1]</sup>
-----------------	--

End point description:

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	9	9		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With at Least one AE for IgPro20

End point title	Percentage of Subjects With at Least one AE for IgPro20 <sup>[2]</sup>
-----------------	--

End point description:

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: percentage of subjects				
number (not applicable)	69.2	69.2		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Subjects With at Least one Treatment-Emergent Adverse Event (TEAE) for IgPro20

End point title	Number of Subjects With at Least one Treatment-Emergent
-----------------	---

## End point description:

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

## End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

## Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	9	9		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With at Least one TEAE for IgPro20

End point title	Percentage of Subjects With at Least one TEAE for IgPro20 <sup>[4]</sup>
-----------------	--

## End point description:

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

## End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

## Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: percentage of subjects				
number (not applicable)	69.2	69.2		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Subjects With at Least one Serious Adverse Event (SAE) for IgPro20

End point title	Number of Subjects With at Least one Serious Adverse Event (SAE) for IgPro20 <sup>[5]</sup>
-----------------	---

End point description:

An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	2	3		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With at Least one SAE for IgPro20

End point title	Percentage of Subjects With at Least one SAE for IgPro20 <sup>[6]</sup>
-----------------	---

End point description:

An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: percentage of subjects				
number (not applicable)	15.4	23.1		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Subjects With at Least one Adverse Events of Special Interest (AESI) for IgPro20

End point title	Number of Subjects With at Least one Adverse Events of Special Interest (AESI) for IgPro20 <sup>[7]</sup>
-----------------	---

End point description:

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	0	1		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With at Least one AESI for IgPro20

End point title	Percentage of Subjects With at Least one AESI for IgPro20 <sup>[8]</sup>
-----------------	--

**End point description:**

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

**End point timeframe:**

From first dose of study drug through last follow-up visit (up to 36 weeks)

**Notes:**

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: percentage of subjects				
number (not applicable)	0	7.7		

**Statistical analyses**

No statistical analyses for this end point

**Primary: Number of Subjects With AEs Categorized as Infusion Site Reactions (ISRs) for IgPro20**

End point title	Number of Subjects With AEs Categorized as Infusion Site Reactions (ISRs) for IgPro20 <sup>[9]</sup>
-----------------	--

**End point description:**

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

**End point timeframe:**

From first dose of study drug through last follow-up visit (up to 36 weeks)

**Notes:**

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	2	3		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With AEs Categorized as ISRs for IgPro20

End point title	Percentage of Subjects With AEs Categorized as ISRs for IgPro20 <sup>[10]</sup>
-----------------	---

End point description:

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: percentage of subjects				
number (not applicable)	15.4	23.1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Rate of ISRs per Infusion for IgPro20

End point title	Rate of ISRs per Infusion for IgPro20 <sup>[11]</sup>
-----------------	---

End point description:

ISR rate per infusion = total number of ISRs across all subjects while on IgPro20 / total number of IgPro20 Infusions across all subjects. ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 and with ISRs were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.



End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13 <sup>[12]</sup>	13 <sup>[13]</sup>		
Units: ISRs per infusion				
number (not applicable)	0.0057	0.0360		

Notes:

[12] - Overall Number of Units Analysed: 353 Infusions

[13] - Overall Number of Units Analysed: 333 Infusions

## Statistical analyses

No statistical analyses for this end point

### Primary: Time to Onset of ISRs for IgPro20

End point title	Time to Onset of ISRs for IgPro20 <sup>[14]</sup>
-----------------	---

End point description:

ISRs included all events reported within the MedDRA High-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'. Time to onset of ISR since the start of the treatment period was reported.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	2 <sup>[15]</sup>	3 <sup>[16]</sup>		
Units: days				
median (full range (min-max))	2 (1 to 3)	15 (1 to 64)		

Notes:

[15] - Overall Number of Units Analysed: 2 ISRs

[16] - Overall Number of Units Analysed: 12 ISRs

## Statistical analyses

No statistical analyses for this end point

### Primary: Duration of ISRs for IgPro20

End point title	Duration of ISRs for IgPro20 <sup>[17]</sup>
-----------------	--

End point description:

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 and with ISRs were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	2 <sup>[18]</sup>	3 <sup>[19]</sup>		
Units: minutes				
median (full range (min-max))	162.0 (162 to 162)	220.0 (180 to 1170)		

Notes:

[18] - Overall Number of Units Analysed: 2 ISRs

[19] - Overall Number of Units Analysed: 12 ISRs

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Subjects With Clinically Significant Abnormalities in Laboratory Tests for IgPro20

End point title	Number of Subjects With Clinically Significant Abnormalities in Laboratory Tests for IgPro20 <sup>[20]</sup>
-----------------	--

End point description:

Abnormality criteria:Hematology-Hemoglobin:<10 g/dL;Platelet count:<75x10<sup>9</sup>/L or >500x10<sup>9</sup>/L;White Blood Cell Count:<3/>16x10<sup>9</sup>/L;Neutrophils:absolute <1.5x10<sup>9</sup>/L,differential<40%;Lymphocytes:absolute <0.8x10<sup>9</sup>/L,differential <10 or >50%;Biochemistry-Bilirubin:>1.5xupper limit of normal (ULN);Alkaline phosphatase:>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):>3xULN;Screening:AST/ALT >3xULN and TotalBilirubin >2xULN;Urea nitrogen:>2.5xULN; Creatinine,serum>1.5xbaseline assessment/change >0.3mg/dL;Glucose,blood:<55/>160mg/dL;Calcium:<7/>11.5mg/dL;Total protein:<5/>9g/dL; Albumin:<3g/dL;Sodium:<130/>150mmol/L;Potassium:<3/>5.5mmol/L; Uric acid,serum:>10mg/dL Males,>8mg/dL Females;Gamma Glutamyl Transpeptidase:>2.5xULN;Phosphorus,inorganic:<2.5/>5mg/dL;Lactate dehydrogenase:>3xULN;Urinalysis-Protein:>20mg/dL.Safety set.Subjects who received IgPro20 were

End point type	Primary
----------------	---------

End point timeframe:

Up to last follow up visit (approximately 36 weeks)

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

---

**Primary: Number of Subjects With Clinically Significant Changes in Vital Signs for IgPro20**

---

End point title	Number of Subjects With Clinically Significant Changes in Vital Signs for IgPro20 <sup>[21]</sup>
-----------------	---

**End point description:**

Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): <100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase >10 from reference visit; Diastolic BP: <50 mmHg or ≥90 mmHg or ≥90 mmHg and increase >10 from reference visit; Pulse rate: <50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase >15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: > 39-degree Celsius (°C) or <35°C (oral, tympanic, axilla or forehead).

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received Ig Pro20 were analysed.

End point type	Primary
----------------	---------

**End point timeframe:**

From first dose of study drug through last follow-up visit (up to 36 weeks)

**Notes:**

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	0	0		

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Primary: Number of Subjects With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters for IgPro20**

---

End point title	Number of Subjects With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters for IgPro20 <sup>[22]</sup>
-----------------	--

**End point description:**

Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett's formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): >500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline < 60 msec; QTcF: increase from baseline ≥ 60.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received Ig Pro20 were analysed.

End point type	Primary
----------------	---------

**End point timeframe:**

From first dose of study drug through last follow-up visit (up to 36 weeks)

**Notes:**

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	0	1		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Subjects With Clinically Significant Abnormalities in Pulmonary Function Tests (PFTs) for IgPro20

End point title	Number of Subjects With Clinically Significant Abnormalities in Pulmonary Function Tests (PFTs) for IgPro20 <sup>[23]</sup>
-----------------	---

End point description:

PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than 10 percentage points from the reference visit. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received Ig Pro20 were analysed.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only the descriptive analysis was planned to be reported for this endpoint.

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Relative Bioavailability (%F) of IgPro20

End point title	Relative Bioavailability (%F) of IgPro20
-----------------	--

End point description:

Relative bioavailability was calculated using Mixed Model Repeated Measures on Log-transformed Dose-normalized area under the curve to the end of the dosing period [AUC0-tau] following administration of the first dose of IgPro20 in the last week of dosing for Sequence A and / or Sequence B. Relative Bioavailability= (AUCtau IgPro20 (SC)/dose of IgPro20 (SC) / (AUCtau of IgPro10 (IV)/dose of IgPro10 (IV)). Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Number of subjects analysed indicates the number of subjects who received IgPro20 and with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	12		
Units: percentage bioavailability				
geometric mean (confidence interval 95%)	0.831 (0.7343 to 0.9396)	0.698 (0.6235 to 0.7804)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Area Under the Concentration Curve to the end of the Dosing Period (AUC0-tau) for IgPro20

End point title	Area Under the Concentration Curve to the end of the Dosing Period (AUC0-tau) for IgPro20
End point description:	
Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Number of subjects analysed indicates the number of subjects who received IgPro20 and with data available for endpoint analysis.	
End point type	Secondary
End point timeframe:	
Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)	

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	11		
Units: hours*grams per litre (h*g/L)				
geometric mean (confidence interval 95%)	3835.68 (3394.749 to 4333.883)	3581.08 (3326.635 to 3854.997)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro20

End point title	Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro20
-----------------	--

End point description:

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Number of subjects analysed indicates the number of subjects who received IgPro20 and with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	12		
Units: h*g/L				
geometric mean (confidence interval 95%)	5361.61 (4729.962 to 6077.619)	4898.02 (4437.732 to 5406.046)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Plasma Drug Concentration (Cmax) for IgPro20

End point title	Maximum Plasma Drug Concentration (Cmax) for IgPro20
-----------------	--

End point description:

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Number of subjects analysed indicates the number of subjects who received IgPro20 and with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	12		
Units: g/L				
geometric mean (confidence interval 95%)	24.237 (21.6041 to 27.1898)	23.203 (21.7278 to 24.7782)		

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro10**

---

End point title	Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro10
-----------------	---

End point description:

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Number of subjects analysed indicates the number of subjects who received IgPro10 and with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	12		
Units: h*g/L				
geometric mean (confidence interval 95%)	16942.6 (15097.493 to 19013.345)	17672.03 (16402.479 to 19039.837)		

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro10**

---

End point title	Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro10
-----------------	--

End point description:

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Number of subjects analysed indicates the number of subjects who received IgPro10 and with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	12		
Units: h*g/L				
geometric mean (confidence interval 95%)	16520.48 (14742.232 to 18513.218)	17349.72 (15917.101 to 18911.275)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum Plasma Drug concentration (Cmax) for IgPro10

End point title	Maximum Plasma Drug concentration (Cmax) for IgPro10
End point description: Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Number of subjects analysed indicates the number of subjects who received IgPro20 and with data available for endpoint analysis.	
End point type	Secondary
End point timeframe: Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16	

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	12		
Units: g/L				
geometric mean (confidence interval 95%)	47.142 (41.2538 to 53.8713)	44.996 (39.2110 to 51.6340)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With at Least one AE for IgPro10

End point title	Number of Subjects With at Least one AE for IgPro10
End point description: AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.	



End point type	Secondary
End point timeframe:	
From first dose of study drug through last follow-up visit (up to 36 weeks)	

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	5	8		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With at Least one AE for IgPro10

End point title	Percentage of Subjects With at Least one AE for IgPro10
End point description:	
<p>AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.</p> <p>Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.</p>	
End point type	Secondary
End point timeframe:	
From first dose of study drug through last follow-up visit (up to 36 weeks)	

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: percentage of subjects				
number (not applicable)	38.5	57.1		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With at Least one TEAE for IgPro10

End point title	Number of Subjects With at Least one TEAE for IgPro10
End point description:	
<p>AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE</p>	

can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	5	8		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With at Least one TEAE for IgPro10

End point title	Percentage of Subjects With at Least one TEAE for IgPro10
-----------------	---

End point description:

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: percentage of subjects				
number (not applicable)	38.5	57.1		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With at Least one SAE for IgPro10

End point title	Number of Subjects With at Least one SAE for IgPro10
-----------------	--

End point description:

An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	1	1		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With at Least one SAE for IgPro10

End point title	Percentage of Subjects With at Least one SAE for IgPro10
-----------------	--

End point description:

An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: percentage of subjects				
number (not applicable)	7.7	7.1		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With at Least one AESI for IgPro10

End point title	Number of Subjects With at Least one AESI for IgPro10
-----------------	---

End point description:

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With at Least one AESIs for IgPro10

End point title	Percentage of Subjects With at Least one AESIs for IgPro10
-----------------	--

End point description:

AE is any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: percentage of subjects				
number (not applicable)	0	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With AEs Categorized as ISRs for IgPro10

End point title	Number of Subjects With AEs Categorized as ISRs for IgPro10
End point description: ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.	
End point type	Secondary
End point timeframe: From first dose of study drug through last follow-up visit (up to 36 weeks)	

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With AEs Categorized as ISRs for IgPro10

End point title	Percentage of Subjects With AEs Categorized as ISRs for IgPro10
End point description: ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed.	
End point type	Secondary
End point timeframe: From first dose of study drug through last follow-up visit (up to 36 weeks)	

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: percentage of subjects				
number (not applicable)	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Clinically Significant Abnormalities in Laboratory Tests for IgPro10

End point title	Number of Subjects With Clinically Significant Abnormalities in Laboratory Tests for IgPro10
-----------------	--

End point description:

Abnormality criteria:Hematology-Hemoglobin:<10 g/dL;Platelet count:<75x10<sup>9</sup>/L or >500x10<sup>9</sup>/L;White Blood Cell Count:<3/>16x10<sup>9</sup>/L;Neutrophils:absolute <1.5x10<sup>9</sup>/L,differential<40%;Lymphocytes:absolute <0.8x10<sup>9</sup>/L,differential <10 or >50%;Biochemistry-Bilirubin:>1.5xupper limit of normal (ULN);Alkaline phosphatase:>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):>3xULN;Screening:AST/ALT >3xULN and TotalBilirubin >2xULN;Urea nitrogen:>2.5xULN; Creatinine,serum>1.5xbaseline assessment/change >0.3mg/dL;Glucose,blood:<55/>160mg/dL;Calcium:<7/>11.5mg/dL;Total protein: <5/>9g/dL; Albumin:<3g/dL;Sodium:<130/>150mmol/L;Potassium:<3/>5.5mmol/L; Uric acid,serum:>10mg/dL Males,>8mg/dL Females;Gamma Glutamyl Transpeptidase:>2.5xULN;Phosphorus,inorganic:<2.5/>5mg/dL;Lactate dehydrogenase:>3xULN;Urinalysis-Protein:>20mg/dL.Safety set.Subjects who received IgPro10 were

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Clinically Significant Changes in Vital Signs for IgPro10

End point title	Number of Subjects With Clinically Significant Changes in Vital Signs for IgPro10
-----------------	---

End point description:

Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): <100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase >10 from reference visit;

Diastolic BP: <50 mmHg or ≥90 mmHg or ≥90 mmHg and increase >10 from reference visit; Pulse rate: <50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase >15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: > 39-degree Celsius (°C ) or <35°C (oral, tympanic, axilla or forehead).  
Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received Ig Pro10 were analysed.

End point type	Secondary
End point timeframe:	
From first dose of study drug through last follow-up visit (up to 36 weeks)	

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Clinically Significant Abnormalities in ECG Parameters for IgPro10

End point title	Number of Subjects With Clinically Significant Abnormalities in ECG Parameters for IgPro10
-----------------	--

End point description:

Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): >500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline < 60 msec; QTcF: increase from baseline ≥ 60.

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received Ig Pro10 were analysed.

End point type	Secondary
End point timeframe:	
From first dose of study drug through last follow-up visit (up to 36 weeks)	

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Clinically Significant Abnormalities in PFTs for IgPro10

End point title	Number of Subjects With Clinically Significant Abnormalities in PFTs for IgPro10
-----------------	--

End point description:

PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than 10 percentage points from the reference visit. Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received Ig Pro10 were analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through last follow-up visit (up to 36 weeks)

End point values	Sequence A: IgPro10	Sequence B: IgPro10		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	14		
Units: subjects	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Minimum Plasma Drug Concentration (Ctough) for IgPro20 in Sequence A

End point title	Minimum Plasma Drug Concentration (Ctough) for IgPro20 in Sequence A
-----------------	--

End point description:

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro20 were analysed. 'Number analysed (n)' indicates the number of subjects with data available for analysis at the specified time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-injection in Weeks 5, 9, 13 and 14

End point values	Sequence A: IgPro20			
Subject group type	Subject analysis set			
Number of subjects analysed	13			
Units: g/L				
geometric mean (full range (min-max))				
Week 5 (n=12)	22.046 (16.69 to 63.70)			
Week 9	21.950 (14.71 to 30.51)			



Week 13 (n=12)	22.354 (16.98 to 31.36)			
Week 14 (n=12)	21.814 (14.49 to 27.93)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Minimum Plasma Drug Concentration (Ctough) for IgPro20 in Sequence B

End point title	Minimum Plasma Drug Concentration (Ctough) for IgPro20 in Sequence B
-----------------	--

End point description:

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. 'Number of subjects analysed' indicates the number of subjects who received IgPro20 and with data available for endpoint analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-injection at Week 21, 25, 29, and 30

End point values	Sequence B: IgPro20			
Subject group type	Subject analysis set			
Number of subjects analysed	12			
Units: g/L				
geometric mean (full range (min-max))				
Week 21	20.427 (12.82 to 25.48)			
Week 25	21.603 (16.92 to 30.49)			
Week 29	21.903 (18.89 to 28.47)			
Week 30	20.497 (18.15 to 23.59)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Minimum Plasma Drug Concentration (Ctough) for IgPro10 in Sequence A

End point title	Minimum Plasma Drug Concentration (Ctough) for IgPro10 in Sequence A
-----------------	--

End point description:

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. Subjects who received IgPro10 were analysed. 'Number analysed (n)' indicates the number of subjects with data available for analysis at the specified time point.

End point type	Secondary
End point timeframe:	
Pre-infusion at Weeks 21, 25 and 29	

<b>End point values</b>	Sequence A: IgPro10			
Subject group type	Subject analysis set			
Number of subjects analysed	13			
Units: g/L				
geometric mean (full range (min-max))				
Week 21 (n=12)	16.123 (9.69 to 34.70)			
Week 25	17.497 (8.80 to 54.96)			
Week 29	16.838 (8.51 to 58.16)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Minimum Plasma Drug Concentration (Ctough) for IgPro10 in Sequence B

End point title	Minimum Plasma Drug Concentration (Ctough) for IgPro10 in Sequence B
End point description:	
Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10. 'Number of subjects analysed' indicates the number of subjects who received IgPro10 and with data available for endpoint analysis. 'Number analysed (n)' indicates the number of subjects with data available for analysis at the specified time point.	
End point type	Secondary
End point timeframe:	
Pre-infusion at Week 5, 9 and 13	

<b>End point values</b>	Sequence B: IgPro20			
Subject group type	Subject analysis set			
Number of subjects analysed	13			
Units: g/L				
geometric mean (full range (min-max))				
Week 5 (n=12)	17.104 (12.77 to 24.04)			
Week 9	17.744 (13.92 to 23.36)			
Week 13	17.113 (12.89 to 25.43)			

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Rate of ISRs per Subject for IgPro20

End point title	Rate of ISRs per Subject for IgPro20
-----------------	--------------------------------------

End point description:

9999= Data was not collected for this endpoint.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

From first dose of study drug through last follow up visit (up to 36 weeks)

End point values	Sequence A: IgPro20	Sequence B: IgPro20		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	13	13		
Units: percent				
number (not applicable)	9999	9999		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug through last follow up visit (up to 36 weeks)

Adverse event reporting additional description:

Safety analysis set included all subjects who received at least 1 infusion of IgPro20 or IgPro10.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

### Reporting groups

Reporting group title	Sequence A: IgPro10
-----------------------	---------------------

Reporting group description:

Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 2.

Reporting group title	Sequence A: IgPro20
-----------------------	---------------------

Reporting group description:

Subjects received IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 1.

Reporting group title	Sequence B: IgPro10
-----------------------	---------------------

Reporting group description:

Subjects received IgPro10 of a total dose of 2 g/kg over 2-5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1.

Reporting group title	Sequence B: IgPro20
-----------------------	---------------------

Reporting group description:

Subjects received IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.

Serious adverse events	Sequence A: IgPro10	Sequence A: IgPro20	Sequence B: IgPro10
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 13 (7.69%)	2 / 13 (15.38%)	1 / 14 (7.14%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial infarction			

subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic gastritis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Interstitial lung disease			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Viral infection			

subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Sequence B: IgPro20		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 13 (23.08%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial ischaemia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			

Upper gastrointestinal haemorrhage subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic gastritis subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Interstitial lung disease subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Viral infection subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Sequence A: IgPro10	Sequence A: IgPro20	Sequence B: IgPro10
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 13 (38.46%)	8 / 13 (61.54%)	8 / 14 (57.14%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Seborrhoeic keratosis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
General disorders and administration site conditions			
Infusion site pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 13 (7.69%) 1	0 / 14 (0.00%) 0
Infusion site swelling subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Infusion site haemorrhage subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Infusion site reaction subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Infusion site vesicles subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Injection site hypersensitivity subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 13 (7.69%) 1	0 / 14 (0.00%) 0
Injection site mass subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1
Infusion site discharge subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Infusion site erosion			



subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Infusion site erythema subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Epistaxis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 2
Dyspnoea subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 13 (7.69%) 1	0 / 14 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 13 (7.69%) 1	0 / 14 (0.00%) 0
Psychiatric disorders Depressed mood subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1
Investigations Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 2
Injury, poisoning and procedural complications Contusion subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1
Fall subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 13 (0.00%) 0	0 / 14 (0.00%) 0
Skin abrasion subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1

Nervous system disorders			
Headache			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	5 / 14 (35.71%)
occurrences (all)	0	1	11
Anosmia			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Sciatica			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Somnolence			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Lymphadenopathy			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	2 / 14 (14.29%)
occurrences (all)	0	1	2
Abdominal pain			
subjects affected / exposed	0 / 13 (0.00%)	2 / 13 (15.38%)	0 / 14 (0.00%)
occurrences (all)	0	2	0
Nausea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	3

Toothache			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Abdominal distension			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Colitis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Eructation			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Haematemesis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Saliva altered			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hypertransaminasaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Dermatitis allergic			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Dermatitis psoriasiform			

subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Lichenoid keratosis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Night sweats			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Purpura			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	0 / 13 (0.00%)	1 / 13 (7.69%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Scleroderma associated digital ulcer			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Skin exfoliation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Umbilical erythema			
subjects affected / exposed	1 / 13 (7.69%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 13 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Myalgia			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1
Neck pain subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1
Pain in extremity subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1
Infections and infestations COVID-19 subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 13 (7.69%) 1	0 / 14 (0.00%) 0
Gingivitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 13 (7.69%) 1	0 / 14 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 13 (0.00%) 0	1 / 14 (7.14%) 1

<b>Non-serious adverse events</b>	Sequence B: IgPro20		
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 13 (46.15%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Seborrhoeic keratosis subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
General disorders and administration site conditions Infusion site pain subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 2		
Infusion site swelling subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 3		

Infusion site haemorrhage subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Infusion site reaction subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Infusion site vesicles subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Injection site hypersensitivity subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0		
Injection site mass subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0		
Pyrexia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0		
Infusion site discharge subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Infusion site erosion subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Infusion site erythema subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Fatigue subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Respiratory, thoracic and mediastinal disorders			

Epistaxis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Dyspnoea			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Investigations			
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Fall			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Skin abrasion			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Anosmia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Dizziness			

subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Sciatica			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Lymphadenopathy			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Toothache			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Abdominal distension			



subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Colitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Eructation			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Haematemesis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Haemorrhoids			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Saliva altered			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Hypertransaminasaemia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Dermatitis allergic			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Dermatitis psoriasiform			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Lichenoid keratosis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Night sweats			

subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Purpura			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Scleroderma associated digital ulcer			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Skin exfoliation			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Umbilical erythema			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Pain in extremity			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0		
Infections and infestations			
COVID-19			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Gingivitis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Lower respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 July 2019	<ul style="list-style-type: none"><li>• Addition of text regarding identified risk of Thromboembolic events (TEE) in treatment population, including new exclusion criteria, monitoring, and study stopping rules</li><li>• Expansion of hemolysis testing as a safety assessment during IgPro20 treatment</li><li>• Clarification of timing for study endpoint measures</li><li>• Addition of exclusion criterion to address use of contraception by potential male subjects</li><li>• Addition of exclusion criteria to address subjects with potential risks of TEE</li><li>• Addition of deoxy ribonucleic acid (DNA) and ribonucleic acid (RNA) as biomarkers and additional collection of whole blood to obtain DNA and RNA</li><li>• Addition of TEEs as an AESI.</li></ul>
07 November 2019	<ul style="list-style-type: none"><li>• Modification of Primary and Secondary Endpoints to include summaries of TEAEs, SAEs, and AESIs</li><li>• Addition of rules for stopping infusion of IgPro20 or IgPro10 and discontinuation of treatment</li><li>• Addition of text and assessments to monitor renal safety</li><li>• Addition and classification of hemolysis and potential acute renal injury as AESIs</li><li>• Addition of guidance regarding the maximum infusion rate for subjects with renal dysfunction</li><li>• Addition of maximum doses of IgPro20 and IgPro10, based on body weight</li><li>• Removal of DLCO assessment at Baseline</li><li>• Clarification of the method of scoring for manual muscle testing</li><li>• Addition of interim analysis.</li></ul>
21 October 2020	<ul style="list-style-type: none"><li>• Defined adjustments that are effective during the Coronavirus disease 2019 (COVID-19) pandemic and provided detailed guidance and procedures that allowed investigators the flexibility to complete critical protocol safety and efficacy assessments while limiting subject exposure to COVID-19 at study sites.</li></ul>
22 February 2021	<ul style="list-style-type: none"><li>• Added guidance regarding dispensing Investigational product (IP) to subjects during a state of emergency or public health crisis</li><li>• Added an option for remote visits during a state of emergency or public health crisis</li><li>• Revised contingencies that were effective during a state of emergency or a public health crisis.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
21 April 2020	Due to COVID-19, enrollment was stopped on 1 Apr 2020, with study timelines re-baselining 25 Jun 2020.	25 June 2020

Notes:

### Limitations and caveats

None reported

